Lung Cancer Clinical Trials in High Point, NC

Lung Cancer Clinical Trials in High Point, NC

View the best 10 lung cancer medical studies in High Point, North Carolina. Access promising new therapies by applying to a High Point-based Lung Cancer clinical trial.

Trials in High Point, North Carolina

Here are the top 10 medical studies for lung cancer in High Point, North Carolina

Image of Alaska Oncology and Hematology, LLC. in Anchorage, United States.

Sacituzumab Govitecan-hziy (SG) +3 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial is testing a new combination therapy for advanced or metastatic non-small-cell lung cancer (NSCLC) that has not responded to other treatments. The primary objectives are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of the new therapy.
Image of Research Site in San Diego, United States.

Durvalumab +2 More

Checkpoint Inhibitor

Recruiting1 awardPhase 3
This trial is testing two drug combinations to help the immune system fight advanced lung cancer that can't be surgically removed. The patients have already had previous treatment without their disease getting worse. The drugs aim to boost the immune response to better identify and kill cancer cells.
Image of Research Site in Chandler, United States.

Durvalumab +2 More

Checkpoint Inhibitor

Recruiting1 awardPhase 3
This trial is testing a new cancer treatment (durvalumab with SoC SBRT) against the current best treatment (placebo with SoC SBRT) for early stage non-small cell lung cancer.
Image of Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, United States.

Pembrolizumab

Checkpoint Inhibitor

Recruiting2 awardsPhase 3
This trial is comparing immunotherapy with or without radiation therapy for stage IV non-small cell lung cancer.
Image of University of South Alabama, Mitchell Cancer Institute ( Site 0003) in Mobile, United States.

Pembrolizumab +6 More

Checkpoint Inhibitor

Recruiting1 awardPhase 3
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Image of Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, United States.

Pembrolizumab +4 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial is comparing how well two groups of cancer patients respond to immunotherapy. One group has cancer that is not as advanced, and the other group has cancer that is more advanced. The goal is to show that the group with more advanced cancer does just as well as the other group when treated with immunotherapy.
Image of Alaska Oncology and Hematology, LLC. in Anchorage, United States.

Sacituzumab Govitecan-hziy (SG) +1 More

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial will compare overall survival of two treatments for lung cancer patients who have progressed after other treatments.
Image of Reading Hospital in West Reading, United States.

Durvalumab +6 More

Immunotherapy

Recruiting2 awardsPhase 3
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Image of Moffitt Cancer Center in Tampa, United States.

Durvalumab +1 More

Checkpoint Inhibitor

Recruiting1 awardPhase 1
This trial will investigate the effects of a combination of drugs (immunotherapy, platinum doublet chemotherapy, and abequolixron) to treat non-small cell lung cancer before surgery.
Image of Virginia Commonwealth University in Richmond, United States.

Patient Navigation

Recruiting1 award6 criteria
This trial tested if a patient navigation program improved the proportion of patients who completed lung cancer screening (LDCT).

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.